Fosinopril as a possible pemphigus-inducing drug

Aurora Parodi, E. Cozzani, G. Milesi, M. Drosera, A. Rebora

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fosinopril has recently been added to the angiotensin-converting enzyme inhibitors inducing pemphigus. The observation of a patient in whom pemphigus vulgaris (PV) worsened after taking fosinopril prompted us to study an experimental way to assess its responsibility. Slices of normal human skin (NHS) were simultaneously incubated for 2, 6, 12 and 24 h at 4°C with progressively diluted fosinopril and captopril solutions and used as indirect immunofluorescence (IIF) substrates for 2 sera containing anti-desmoglein-3 (anti-Dsg3) antibodies at a dilution of 1/160. With captopril, IIF was negative, irrespective of dilution and time of incubation. Only at 1/40,000 dilution was IIF positive. With fosinopril, IIF was negative for the 2- and 6-hour-long incubations but turned positive after 12 h and so remained with all other solutions and incubation times. IIF negativity with captopril suggests that anti-Dsg3 antibodies contained in the PV sera were unable to find molecules in NHS to bind to. Captopril would therefore induce acantholysis by blocking the adhesion molecules. With fosinopril, instead, a partial block of the adhesion molecules was seen only with the very concentrated solution, unlikely to occur in vivo. Fosinopril, therefore, is probably unable to block the adhesion molecules in vivo. Our method might be used to verify the acantholytic properties of a drug.

Original languageEnglish
Pages (from-to)139-141
Number of pages3
JournalDermatology
Volume204
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Fosinopril
Pemphigus
Indirect Fluorescent Antibody Technique
Captopril
Desmoglein 3
Pharmaceutical Preparations
Acantholysis
Skin
Antibodies
Serum
Angiotensin-Converting Enzyme Inhibitors
Observation

Keywords

  • Captopril
  • Fosinopril
  • Immunofluorescence
  • Pemphigus

ASJC Scopus subject areas

  • Dermatology

Cite this

Parodi, A., Cozzani, E., Milesi, G., Drosera, M., & Rebora, A. (2002). Fosinopril as a possible pemphigus-inducing drug. Dermatology, 204(2), 139-141. https://doi.org/10.1159/000051833

Fosinopril as a possible pemphigus-inducing drug. / Parodi, Aurora; Cozzani, E.; Milesi, G.; Drosera, M.; Rebora, A.

In: Dermatology, Vol. 204, No. 2, 2002, p. 139-141.

Research output: Contribution to journalArticle

Parodi, A, Cozzani, E, Milesi, G, Drosera, M & Rebora, A 2002, 'Fosinopril as a possible pemphigus-inducing drug', Dermatology, vol. 204, no. 2, pp. 139-141. https://doi.org/10.1159/000051833
Parodi A, Cozzani E, Milesi G, Drosera M, Rebora A. Fosinopril as a possible pemphigus-inducing drug. Dermatology. 2002;204(2):139-141. https://doi.org/10.1159/000051833
Parodi, Aurora ; Cozzani, E. ; Milesi, G. ; Drosera, M. ; Rebora, A. / Fosinopril as a possible pemphigus-inducing drug. In: Dermatology. 2002 ; Vol. 204, No. 2. pp. 139-141.
@article{c4d9f4291eff4a0495431aacb7c927ef,
title = "Fosinopril as a possible pemphigus-inducing drug",
abstract = "Fosinopril has recently been added to the angiotensin-converting enzyme inhibitors inducing pemphigus. The observation of a patient in whom pemphigus vulgaris (PV) worsened after taking fosinopril prompted us to study an experimental way to assess its responsibility. Slices of normal human skin (NHS) were simultaneously incubated for 2, 6, 12 and 24 h at 4°C with progressively diluted fosinopril and captopril solutions and used as indirect immunofluorescence (IIF) substrates for 2 sera containing anti-desmoglein-3 (anti-Dsg3) antibodies at a dilution of 1/160. With captopril, IIF was negative, irrespective of dilution and time of incubation. Only at 1/40,000 dilution was IIF positive. With fosinopril, IIF was negative for the 2- and 6-hour-long incubations but turned positive after 12 h and so remained with all other solutions and incubation times. IIF negativity with captopril suggests that anti-Dsg3 antibodies contained in the PV sera were unable to find molecules in NHS to bind to. Captopril would therefore induce acantholysis by blocking the adhesion molecules. With fosinopril, instead, a partial block of the adhesion molecules was seen only with the very concentrated solution, unlikely to occur in vivo. Fosinopril, therefore, is probably unable to block the adhesion molecules in vivo. Our method might be used to verify the acantholytic properties of a drug.",
keywords = "Captopril, Fosinopril, Immunofluorescence, Pemphigus",
author = "Aurora Parodi and E. Cozzani and G. Milesi and M. Drosera and A. Rebora",
year = "2002",
doi = "10.1159/000051833",
language = "English",
volume = "204",
pages = "139--141",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Fosinopril as a possible pemphigus-inducing drug

AU - Parodi, Aurora

AU - Cozzani, E.

AU - Milesi, G.

AU - Drosera, M.

AU - Rebora, A.

PY - 2002

Y1 - 2002

N2 - Fosinopril has recently been added to the angiotensin-converting enzyme inhibitors inducing pemphigus. The observation of a patient in whom pemphigus vulgaris (PV) worsened after taking fosinopril prompted us to study an experimental way to assess its responsibility. Slices of normal human skin (NHS) were simultaneously incubated for 2, 6, 12 and 24 h at 4°C with progressively diluted fosinopril and captopril solutions and used as indirect immunofluorescence (IIF) substrates for 2 sera containing anti-desmoglein-3 (anti-Dsg3) antibodies at a dilution of 1/160. With captopril, IIF was negative, irrespective of dilution and time of incubation. Only at 1/40,000 dilution was IIF positive. With fosinopril, IIF was negative for the 2- and 6-hour-long incubations but turned positive after 12 h and so remained with all other solutions and incubation times. IIF negativity with captopril suggests that anti-Dsg3 antibodies contained in the PV sera were unable to find molecules in NHS to bind to. Captopril would therefore induce acantholysis by blocking the adhesion molecules. With fosinopril, instead, a partial block of the adhesion molecules was seen only with the very concentrated solution, unlikely to occur in vivo. Fosinopril, therefore, is probably unable to block the adhesion molecules in vivo. Our method might be used to verify the acantholytic properties of a drug.

AB - Fosinopril has recently been added to the angiotensin-converting enzyme inhibitors inducing pemphigus. The observation of a patient in whom pemphigus vulgaris (PV) worsened after taking fosinopril prompted us to study an experimental way to assess its responsibility. Slices of normal human skin (NHS) were simultaneously incubated for 2, 6, 12 and 24 h at 4°C with progressively diluted fosinopril and captopril solutions and used as indirect immunofluorescence (IIF) substrates for 2 sera containing anti-desmoglein-3 (anti-Dsg3) antibodies at a dilution of 1/160. With captopril, IIF was negative, irrespective of dilution and time of incubation. Only at 1/40,000 dilution was IIF positive. With fosinopril, IIF was negative for the 2- and 6-hour-long incubations but turned positive after 12 h and so remained with all other solutions and incubation times. IIF negativity with captopril suggests that anti-Dsg3 antibodies contained in the PV sera were unable to find molecules in NHS to bind to. Captopril would therefore induce acantholysis by blocking the adhesion molecules. With fosinopril, instead, a partial block of the adhesion molecules was seen only with the very concentrated solution, unlikely to occur in vivo. Fosinopril, therefore, is probably unable to block the adhesion molecules in vivo. Our method might be used to verify the acantholytic properties of a drug.

KW - Captopril

KW - Fosinopril

KW - Immunofluorescence

KW - Pemphigus

UR - http://www.scopus.com/inward/record.url?scp=0036215629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036215629&partnerID=8YFLogxK

U2 - 10.1159/000051833

DO - 10.1159/000051833

M3 - Article

C2 - 11937741

AN - SCOPUS:0036215629

VL - 204

SP - 139

EP - 141

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -